Key Takeaways
- Domestic brands drove growth, exports dragged: ZIFI, Electral and Enerzal powered domestic revenue, while US export de-growth on price and competition pulled the other way. A one-off Rs. 11.7 cr COVID inventory provision and US mix shift compressed gross margins.
- Margins under multi-front pressure: EBITDA margin fell to 5% in Q4, hit by the inventory provision, lower high-margin US sales, and broad-based input-cost inflation. Management called the cost environment unpredictable and declined to guide on margin recovery.
- FY23 outlook is internally confident but externally guarded: Management has factored in growth but refuses to give any top-line guidance, citing an unpredictable post-COVID market where April industry data already showed high negative growth.
- Portfolio reshaping is underway: Two new divisions launched (Nutrica, Zocon dermatology), Favipiravir exited, EnteroPlus SKUs expanded, and dermatology products consolidated into one basket. The US strategy stays partner-led with an option to go direct.
- What to watch next quarter: Whether the US export base stabilizes at the March '21 level as promised, any signal on input-cost direction, and early traction in the new Nutrica and Zocon divisions.
Domestic Performance & Brand Dynamics
- Large brands carried the quarter: ZIFI, Electral and Enerzal were the named domestic growth drivers, with Zifi and Electral maintaining market leadership in their doctor/chemist domains.
- Enerzal lost share in the wider market: The energy drink category is not 100% prescription-driven, so new entrants erode share in the broad market even though the doctor-and-chemist franchise held. The company is working aggressively to regain share.
- Favipiravir exit was a deliberate marketing call: FDC earned ~Rs. 18 cr from Favipiravir in FY22 but withdrew completely because current case numbers in India no longer justify direct treatment. All backlogs were cleared in the March quarter.
- COVID portfolio beyond Favipiravir is stable: Antibiotics and co-therapies that gained traction during COVID from allied prescriptions are not impacted with or without COVID, so that base is not at risk.
- MR count rose, not fell: The 3,242 figure represents only grassroot MRs; the earlier ~4,000 figure likely included the total field force. MR numbers actually increased by ~500 in FY22 due to the Nutrica and Zocon division launches.
Mayank Tikkha: "It is not a 100% prescription driven market of energy drinks. That is the reason why we have lost but the domain at which we operate that is the doctor fraternity and the chemist business probably we have not lost any market share but to be fair we have given you the market dynamics overall."
Export & US Strategy
- US drove the QoQ export uptick but dragged YoY: Export formulations rose from Rs. 37 cr to Rs. 47 cr QoQ on US contribution, but the YoY decline was attributed to price pressure and lower demand from competition. March '21 is the base management wants investors to use for future growth.
- US remains a key focus market: Management called the US particularly lucrative from a bottom-line perspective and will continue registering products, owning ANDAs, and partnering with existing and possibly new partners.
- Direct presence is not ruled out: The company is still open to being directly present in the US, though right now it is happy with the partner model. Specialty eye drops and ophthalmic products are the preferred categories; generic me-too products are seen as a very difficult, competitive market.
- International ambition is broad-based: Beyond the US, the company sees significant potential in regulated markets like the UK and smaller/less regulated markets. It has started investing in promotion in markets such as Myanmar and Kenya, and expects international business to grow meaningfully over 3–5 years.
- South Africa will take 2–3 years: A new hire has been made to lead the subsidiary, which management sees as a potential head office for the entire Southern part of the continent. Things are starting to look better but the turnaround is a multi-year project.
Ameya Chandavarkar: "We have not categorically said that we don't intend to be there ourselves so I'm not sure where you're getting that information from. We are still open to that possibility. However right now we are happy partnering and it's been a very lucrative market for us, particularly from the bottom-line perspective."
Margin & Cost Structure
- Three forces compressed Q4 margins: A one-off Rs. 11.7 cr COVID-related inventory provision (~2% impact), lower revenue from the high-margin US business, and inflationary increases across raw material and packing material.
- Other expenses jumped on normalisation, not waste: Q4 FY22 other expenses of Rs. 111 cr compare to a pre-COVID run-rate of ~Rs. 80 cr, but March '22 revenue was much higher than March '20 and variable/semi-variable costs (marketing, logistics) rose in proportion. The QoQ step-up from Rs. 95–100 cr included ~Rs. 1.5 cr of marketing, plus logistics, admin and CSR costs absent in Q3.
- Logistics costs are structurally higher: Logistics rose to 3.5% of revenue in FY22 from 2.5% in March '21, despite a decrease in export revenue, suggesting domestic freight inflation or mix effects are at work.
- Input-cost visibility is poor: Management said input costs are going up everywhere and it is unsure how they will pan out over the next 12 months, so it will not give margin guidance until the picture clears.
Sanjay Jain: "You are all aware there are input costs are going up everywhere. We are not sure how it will pan out in the next 12 month of period. We have to wait and watch so that we can give you further guidance on that."
Portfolio Reshaping & New Launches
- Two new divisions went live: Nutrica (nutritional basket, IMS products) launched in April FY22 and Zocon (dermatology basket) launched in January FY22. Both added to the MR count and represent fresh growth vectors.
- Dermatology is now a consolidated focus area: Products previously spread across divisions have been consolidated into the Zocon basket, which will also cater to gynaec, GC, and physician specialties. Management intends to grow this franchise further.
- EnteroPlus is getting a second life: Acquired two years back but stalled by COVID lockdowns, the brand is now being taken aggressively with added SKUs (capsule formulation, drops for neonates) and aggressive FY23 targets. It is among the top focused brands but management does not see top-10 potential given the molecule's market size.
- Domestic growth bets for the next 3–5 years: (1) Revamping the antibiotic portfolio to create bigger brands from mid-tier products. (2) Fortifying Electral-Enerzal leadership and regaining share. (3) Building the nutraceutical basket, where first-year results are very encouraging. (4) Gaining share in dermatology. (5) Expanding the cardio-diabeto presence, where the company is present but not yet significant.
Mayank Tikkha: "Very difficult to say, very early days because our top brands already touching Rs. 300 crores what we share. Now this molecule or maybe this product, doesn't have that kind of potential in the market as of now; as of now we are talking about."
Capital Allocation & Infrastructure
- Buyback completed, future returns unclear: The ~Rs. 170 cr buyback was completed in Q4 FY22. When asked about FY23 capital allocation (dividend vs. buyback) given the 12-month cooling-off period, management declined to comment, calling it a board decision.
- Capex cycle is ramping up: FY23 capex is planned at Rs. 120 cr, with the ALP 4 project already budgeted. A similar Rs. 120 cr is likely in FY24, taking the total plan above Rs. 200 cr.
- Oshiwara office building is a ~Rs. 200 cr multi-year project: Construction is at a very early stage on the ~1 lakh sq ft plot and will take 2–2.5 years to complete, including interiors.
- Acquisition appetite exists but nothing is crystallised: Management acknowledged it will look at opportunities that come its way but declined to comment on whether any negotiation is ongoing, saying any deal will be communicated once crystallised.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Export base | March '21 export number can be taken as a base for future growth | Ongoing |
| Capex | Rs. 120 cr planned; similar amount likely in FY24; total plan >Rs. 200 cr | FY23–FY24 |
| Office building | ~Rs. 200 cr construction cost, ~1 lakh sq ft, 2–2.5 years to complete | 2–2.5 years |
| South Africa turnaround | New hire in place; will take at least 2–3 years to turn the business around | 2–3 years |
| International business growth | Expect meaningful growth over the next 3–5 years | 3–5 years |
| Domestic growth drivers | Five focus categories (antibiotics, Electral-Enerzal, nutraceuticals, dermatology, cardio-diabeto) to drive growth over next 2–3 to 5 years | 2–5 years |
| IPM outperformance | Internally confident of growing ahead of IPM in FY23-24, but cannot guarantee any number because the post-COVID market is behaving in a very uncertain manner | FY23–FY24, conditional on market stability |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue growth | 9% YoY; 15% for FY22 year-end |
| Domestic formulation growth | 18% YoY; 31% for FY22 year-end |
| Export formulation growth | -15% YoY; -35% for FY22 year-end |
| Export formulation revenue | ₹47 cr, up from ₹37 cr in Q3 FY22 |
| EBITDA margin | 5% for Q4 FY22; 16% for FY22 year-end |
| Employee cost | 22% of revenue, stable |
| Gross margin impact: COVID inventory provision | ₹11.70 cr one-off provision, ~2% impact on gross margin |
| Gross margin impact: raw material inflation | 1% to 1.5% on a quarter and YoY basis |
| India portfolio weighted average price increase | 5% to 6% (₹70–80 cr annualized) |
| NLEM price increase | 10.7% |
| Non-NLEM price increase | 10% wherever possible |
| Logistic costs as a percentage of revenue | 3.5% in FY22, up from 2.5% in FY21 |
| CAPEX plan for FY23 | ₹120 cr; similar expected for FY24, total plan over ₹200 cr |
| Cash balance | ~₹750 cr post-buyback (₹850 cr before buyback of ~₹170 cr) |
| Medical representatives | 3,242; total field force increased by ~500 in FY22 |
| R&D expenditure | 2% of revenue |
| Favipiravir revenue | ~₹18 cr in FY22 |
| US share of export formulation revenue | 50% in Q4 FY22 |